Nyrada (ASX:NYR) received human research ethics committee approval to modify its phase one clinical trial protocol, according to a Wednesday Australian bourse filing.
The amendments allow for the evaluation of the safety, tolerability, and pharmacokinetics of Xolatryp, a small-molecule cardioprotection and neuroprotection therapy candidate, in healthy volunteers at higher doses and over a longer infusion duration.
The phase one trial will consist of six cohorts, and results are expected in the September quarter.
The amended protocol will give the firm greater flexibility in designing a phase two trial, including the ability to optimize dosing for the target patient population, per the filing.
The firm's shares fell 3% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.